Hepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)

Resistance to sorafenib remains one of the biggest concerns for hepatocellular carcinoma treatment. In article number 2003042, Xiao Xu, Jiajia Xiang, and co‐workers developed a self‐activated sorafenib and USP22 shRNA codelivery nanoplatform (Gal‐SLP) to reverse cancer stemness and sensitive cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Sci (Weinh)
Main Authors: Xu, Shengjun, Ling, Sunbin, Shan, Qiaonan, Ye, Qianwei, Zhan, Qifan, Jiang, Guangjiang, Zhuo, Jianyong, Pan, Binhua, Wen, Xue, Feng, Tingting, Lu, Haohao, Wei, Xuyong, Xie, Haiyang, Zheng, Shusen, Xiang, Jiajia, Shen, Youqing, Xu, Xiao
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Cover Picture
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7927629/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.202170022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados